Lenz Therapeutics stock hits 52-week high at 42.79 USD

Lenz Therapeutics Inc (market cap: $1.2B) has seen its stock reach a 52-week high of 42.79 USD, marking a significant milestone for the company. According to InvestingPro data, analysts maintain a bullish outlook with price targets reaching as high as $60. Over the past year, Lenz Therapeutics has experienced a substantial increase in its stock value, with a 1-year return exceeding 96%. This impressive growth highlights the company’s strong financial health, supported by a robust current ratio of 20.54 and minimal debt exposure. The recent peak in stock price reflects positive market sentiment, though InvestingPro analysis indicates current trading levels are near Fair Value. InvestingPro subscribers have access to 12 additional key insights about LENZ, including detailed profitability metrics and growth forecasts.

In other recent news, LENZ Therapeutics has achieved a significant milestone with the FDA’s approval of VIZZ, an aceclidine-based ophthalmic solution for treating presbyopia. This approval marks VIZZ as the first eye drop treatment of its kind for adults with blurry near vision. LENZ plans to make VIZZ samples available in the United States by October 2025, with a full commercial launch anticipated by the end of the year. In light of this development, H.C. Wainwright has raised its price target for LENZ Therapeutics from $48 to $56, maintaining a Buy rating and identifying the company as one of its top picks for the second half of 2025. Additionally, LENZ Therapeutics reported a second-quarter loss of $0.53 per share as it prepares for the potential commercial launch of LNZ100, another aceclidine-based eye drop. The company confirmed that the FDA review of its New Drug Application for LNZ100 is on track, with a decision expected by August 2025. LENZ has also completed the hiring and training of an 88-member sales force, readying itself for immediate commercialization upon approval. The company concluded the quarter with a solid cash reserve of $209.6 million, which is expected to sustain operations until the company achieves positive cash flow post-launch.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.